Improving treatment for Thymidine Kinase 2 deficiency
MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency
This study is testing new treatments for people with Thymidine Kinase 2 (TK2) deficiency, a condition that causes muscle weakness, by using special combinations of nutrients to help their cells make energy better, and it’s designed to be easy to take, even for those who have trouble swallowing.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mitorainbow Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project ID | NIH-10705703 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for Thymidine Kinase 2 (TK2) deficiency, a genetic condition that leads to severe muscle weakness and mitochondrial dysfunction. The approach involves two innovative treatment strategies: substrate enhancement therapy, which uses specific combinations of nucleotides to support mitochondrial DNA synthesis, and molecular bypass therapy, which aims to provide alternative pathways for cellular energy production. Patients with difficulty swallowing may receive these therapies through high-dose oral administration or feeding tubes, making it accessible for those in need.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with Thymidine Kinase 2 deficiency, particularly those experiencing severe symptoms and difficulties with swallowing.
Not a fit: Patients without a diagnosis of TK2 deficiency or those who do not experience significant symptoms related to the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life and longevity for patients suffering from TK2 deficiency.
How similar studies have performed: Previous compassionate use programs have shown promising results with similar therapeutic approaches, indicating potential for success in this research.
Where this research is happening
Cary, United States
- Mitorainbow Therapeutics, INC. — Cary, United States (Active)
Researchers
- Principal investigator: Peterson, Ward — Mitorainbow Therapeutics, INC.
- Study coordinator: Peterson, Ward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.